ProCE Banner Activity

Key Considerations for Managing Patients With CLL/SLL

Clinical Thought

In this brief commentary, expert pharmacists review optimal use of BTK inhibitors and venetoclax plus CD20-targeted antibody therapy in patients with CLL/SLL.

Released: March 08, 2023

Expiration: March 06, 2024

Share

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Disclosure

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: ADC Therapeutics, Genmab.

Caitlin Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.